StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)

Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –

Halozyme Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Halozyme Therapeutics's enterprise value was $13.58B on Nov 11, 2026, against $9.48B a year earlier. Over the last 5 years it ranged from $4.15B to $16.91B, with a median of $7.74B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$13.58B+50.9%
2025Dec 31, 2025$9.00B+21.1%
2024Dec 31, 2024$7.43B+21.7%
2023Dec 29, 2023$6.11B-31.6%
2022Dec 30, 2022$8.93B+80.8%
2021Dec 31, 2021$4.94B-9.1%
2020Dec 31, 2020$5.43B+109.7%
2019Dec 31, 2019$2.59B+20.7%
2018Dec 31, 2018$2.15B-22.7%
2017Dec 29, 2017$2.78B+126.0%
2016Dec 30, 2016$1.23B-43.0%
2015Dec 31, 2015$2.16B+83.7%
2014Dec 31, 2014$1.18B-30.8%
2013Dec 31, 2013$1.70B+153.9%
2012Dec 31, 2012$668.55M-27.3%
2011Dec 30, 2011$919.36M–

More Halozyme Therapeutics figures

See a number that looks wrong?